Pyxis Oncology (NASDAQ:PYXS) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a research note released on Friday morning,Benzinga reports. HC Wainwright currently has a $5.00 target price on the stock, down from their prior target price of $7.00.

PYXS has been the topic of a number of other reports. Stephens started coverage on shares of Pyxis Oncology in a report on Friday, November 8th. They issued an “overweight” rating and a $13.00 target price on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $8.00 price objective (down previously from $10.00) on shares of Pyxis Oncology in a research note on Friday. Finally, William Blair lowered Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $9.43.

Pyxis Oncology Stock Up 9.7 %

Shares of Pyxis Oncology stock opened at $1.69 on Friday. The stock has a market cap of $100.50 million, a P/E ratio of -1.64 and a beta of 1.00. Pyxis Oncology has a 12-month low of $1.49 and a 12-month high of $6.85. The business’s 50 day moving average is $2.93 and its 200-day moving average is $3.30.

Insider Activity at Pyxis Oncology

In other Pyxis Oncology news, CFO Pamela Ann Connealy purchased 88,850 shares of the company’s stock in a transaction dated Tuesday, November 26th. The stock was bought at an average cost of $1.96 per share, for a total transaction of $174,146.00. Following the completion of the transaction, the chief financial officer now owns 1,199,143 shares in the company, valued at approximately $2,350,320.28. This represents a 8.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 9.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Pyxis Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fullcircle Wealth LLC acquired a new position in Pyxis Oncology in the second quarter valued at about $40,000. Bank of New York Mellon Corp lifted its holdings in shares of Pyxis Oncology by 92.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 311,630 shares of the company’s stock worth $1,031,000 after acquiring an additional 149,522 shares during the period. Rhumbline Advisers acquired a new stake in shares of Pyxis Oncology during the 2nd quarter worth approximately $216,000. Pier 88 Investment Partners LLC increased its stake in Pyxis Oncology by 121.4% in the second quarter. Pier 88 Investment Partners LLC now owns 113,700 shares of the company’s stock valued at $376,000 after acquiring an additional 62,340 shares during the last quarter. Finally, American Century Companies Inc. increased its stake in Pyxis Oncology by 56.0% in the second quarter. American Century Companies Inc. now owns 58,252 shares of the company’s stock valued at $193,000 after acquiring an additional 20,901 shares during the last quarter. 39.09% of the stock is owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.